WuXi Biologics (Cayman) Inc.
2269
株式のランク
#991
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
株価
$5.74
時価総額
$23.64B
変化（1日）
-8.79%
変化（1年）
24.58%
国
CN
取引 WuXi Biologics (Cayman) Inc. (2269)
カテゴリー
Healthcare
WuXi Biologics (Cayman) Inc.（2269）の発行済株式数
October 2026 時点の発行済株式数 0
WuXi Biologics (Cayman) Inc. の最新の財務報告および株価によると、現在の発行済株式数は 0 です。October 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
WuXi Biologics (Cayman) Inc.（2269）の発行済株式数の履歴（2014 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2025 | 4.18B | 2.29% |
| 2024 | 4.08B | -1.96% |
| 2023 | 4.16B | -0.22% |
| 2022 | 4.17B | -5.18% |
| 2021 | 4.40B | 4.55% |
| 2020 | 4.21B | 5.30% |
| 2019 | 4.00B | 1.42% |
| 2018 | 3.94B | 22.31% |
| 2017 | 3.22B | -5.29% |
| 2016 | 3.40B | 0.00% |
| 2015 | 3.40B | 0.00% |
| 2014 | 3.40B | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 62.19M | - |
NL
|
|
| - | - |
CH
|
